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Abstract
Background: Although dyslipidemia is related to the pathogenesis of renal insufficiency, which routinely available
lipid measure is more applicable in estimation of kidney function is still uncertain. Our objective was to evaluate
inconsistent associations of lipid profiles with both albuminuria and chronic kidney disease (CKD).
Methods: We performed a population-based study in 9730 subjects aged 40 years or older. Definitions of
abnormalities in albumin excretion were according to the latest guidelines of American Diabetes Association’s
Standards of Medical Care. CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m2
or the presence of albuminuria.
Results: There were 2274 (23.4 %) participants categorized as low-grade albuminuria, 639 (6.6 %) participants
categorized as increased urinary albumin excretion and 689 (7.1 %) participants categorized as CKD. Triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C), Non HDL-C to HDL-C ratio, TG to HDL-C ratio were significantly
correlated with urinary albumin to creatinine ratio (ACR), serum creatinine and eGFR (all P < 0.0001). Compare with
other lipid parameters, TG to HDL-C ratio have shown the strongest correlation with increased odds of both
increased urinary albumin excretion and CKD. No significant associations between lipid parameters and low-grade
albuminuria were observed after adjustments for potential confounding factors.
Conclusion: Our study lends support to discordant associations of lipid parameters with albuminuria and renal
function. TG to HDL-C ratio is a better marker than other routine lipid measures for identifying renal insufficiency
and should be given more consideration in the clinical practice.
Keywords: Dyslipidemia, Low-grade albuminuria, Increased urinary albumin excretion, Chronic kidney disease, TG to
HDL-C ratio
Background
In recent years, chronic kidney disease (CKD) has become
an important public health problem and directly affects
the global burden of death caused by cardiovascular dis-
eases (CVD) [1, 2]. Increased urinary albumin excretion is
including historical micro- and macro-albuminuria, which
is defined as the urinary albumin-to-creatinine ratio
(ACR) ranges greater or equal than 30 mg/g [3]. Studies
conducted over the past decades have provided substantial
evidence that increased urinary albumin excretion is a risk
factor for diabetic nephropathy and cardiovascular
diseases [4–6]. Recent studies indicated that low-grade
albuminuria (ACR less than 30 mg/g) is associated with
abnormal cardiac mechanics and might also increase the
risk of cardiovascular morbidity and mortality [7–9].
As a modifiable risk factors for cardiovascular disease,
controlling of dyslipidemia is one of the most effective
way for preventing atherosclerotic cardiovascular disease
(ASCVD) in subject with chronic renal insufficiency
[10–12]. Atherosclerotic renovascular disease (ARVD) is
a fairly common disorder in elderly people [13].
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However, based on current evidences, the association
between dyslipidemia and ARVD is still not con-
firmed [14, 15]. There is ongoing debate regarding
the importance of lipoprotein subclasses and other re-
lated markers of lipoprotein metabolism. Guidelines
for the detection and treatment of high cholesterol recom-
mend using low density lipoprotein cholesterol (LDL-C)
as the primary marker to guide therapy. In addition to
LDL-C, Non-high density lipoprotein cholesterol (Non-
HDL-C), Non-HDL-C to HDL-C ratio (Non-HDL-C/
HDL-C) and triglyceride to HDL-C ratio (TG/HDL-C) are
routinely available from the standard lipid profiles. Grow-
ing evidences suggests that Non-HDL-C may provide a
more accurate measure of coronary heart disease risk than
LDL-C [16]. However, in patients with type 2 diabetes,
Non-HDL-C/HDL-C is better than Non-HDL-C to
predict coronary heart disease [17]. Based on the above ar-
guments, as ASCVD, ARVD and CKD sharing similar
pathogenesis and common risk factors, we speculated that
the inconsistent association of lipid parameters with
vascular might also existed in renal insufficiency.
Previously existing literature and primary analyses
have not been implemented to make a systematic com-
parison on the association of different lipid markers with
both of the albuminuria and CKD. In practice, however,
it is unclear which routinely available lipid measure is
better for the identification of kidney function. Accord-
ingly, we assessed the associations of all routine lipid
measures with both albuminuria and renal function in a
community-based population.
Methods
Study population and design
We performed a cross-sectional study in a community
in Guangzhou, China from June to November, 2011.
The study population was from the Risk Evaluation of
cAncers in Chinese diabeTic Individuals: A lONgitu-
dinal (REACTION) study, which was been set up as a
multicenter prospective observational study with the
aim of evaluating chronic diseases in the Chinese
population [18, 19]. During the recruiting phase, a
total of 10,104 residents aged 40 years or older were in-
vited to participate by examination notices or home
visits. In total, 9916 subjects signed the consent form and
agreed to participate in the survey, and the participation
rate was 98.1 %. The subjects who failed to provided infor-
mation about lipid parameters (HDL-C: n = 20; LDL-C: n =
1; TG: n = 8) or ACR (n = 157) were excluded from the ana-
lyses. Finally, a total of 9730 eligible individuals were in-
cluded in the data analyses. The study protocol was
approved by the Institutional Review Board of the Sun
Yat-sen Memorial Hospital affiliated with Sun Yat-sen
University and was in accordance with the principles of
the Helsinki Declaration II. Written informed consent was
obtained from each participant prior to data collection.
Clinical and biochemical measurements
A standard questionnaire was administered by trained
staff to collect information about sociodemographic
characteristics, family history and lifestyle factors. Smok-
ing or drinking habits were classified as ‘never’, ‘current’
(smoking or drinking regularly in the past 6 months) or
‘ever’ (cessation of smoking or drinking of more than
6 months) [20]. A short form of the International Physical
Activity Questionnaire (IPAQ) was used to estimate phys-
ical activity during leisure time by adding the results for
questions about the frequency and duration of moderate
or vigorous activities and walking [21]. Metabolic equiva-
lent hours per week (MET-h/week) were calculated separ-
ately to evaluate total physical activity.
All participants completed the anthropometrical mea-
surements with the assistance of trained staff using
standard protocols [18]. Blood pressure was measured
three times consecutively by the same observer with
5 min intervals using an automated electronic device
(OMRON, Omron Company, China). The average of the
three measurements of blood pressure was used for the
analysis. Body height and body weight were recorded to
the nearest 0.1 cm and 0.1 kg, respectively, while partici-
pants were wearing light indoor clothing without shoes.
Body mass indices (BMI) were calculated as the weight
in kilograms divided by the height in meters squared
(kg/m2). Obesity was defined by BMI equal to or greater
than 28, and overweight was defined by BMI equal to or
greater than 24 and less than 28 [22]. Waist circumfer-
ence (WC) was measured at the umbilical level with par-
ticipant in the standing position at the end of a gentle
expiration. All relevant data was recorded into the data-
base by 2 different persons to ascertain results reliability
in the present study. We performed source data con-
firmation including verification of all relevant data and
informed consent of participating participants. Data
queries will be raised for inconsistent, impossible or
missing data to ensure that all data are reliable and have
been processed correctly.
Venous blood samples were collected for laboratory
tests after an overnight fasting of at least 10 h. Measure-
ments of fasting serum insulin, fasting plasma glucose
(FPG), oral glucose tolerance test (OGTT) 2 h glucose,
triglycerides (TG), total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C) and serum creatinine (SCr) were
performed with an autoanalyzer (Beckman CX-7 Bio-
chemical Autoanalyser, Brea, CA, USA). Non-HDL-C
levels were calculated from the difference between
serum TC and HDL-C. Dyslipidemia was determined
if any one of the following indexes was met: TC
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level ≥ 240 mg/dL, LDL-C level ≥ 160 mg/dL, TG
level ≥ 200 mg/dL, HDL-C level < 40 mg/dL or previ-
ously diagnosed dyslipidemia [23]. Hemoglobin A1c
(HbA1c) was assessed by high-performance liquid
chromatography (Bio-Rad, Hercules, CA). The insulin
resistance index (homeostasis model assessment of
insulin resistance, HOMA-IR) was calculated as fast-
ing insulin (μIU/ml) × fasting glucose (mmol/L)/22.5
[24]. Insulin resistance was defined by a HOMA-IR
index within the top quartile (greater than 2.54 in the
present study) [25]. Diabetes was diagnosed according
to the 1999 World Health Organization diagnostic
criteria. The abbreviated Modification of Diet in Renal
Disease (MDRD) formula recalibrated for Chinese
population was used to calculate estimated glomerular
filtration rate (eGFR) expressed in mL/min per 1.73 m2
using a formula of eGFR = 186 × [serum creatinine ×
0.011]-1.154 × [age]-0.203 × [0.742 if female] × 1.233,
where serum creatinine was expressed as μmol/L and
1.233 was the adjusting coefficient for Chinese popula-
tion [26].
Definition of low-grade albuminuria, increased urinary
albumin excretion and chronic kidney disease
Definitions of abnormalities in albumin excretion were
according to the latest guidelines of American Diabetes
Association’s Standards of Medical Care [3]. The first
morning spot urine samples were collected for assessing
the ACR. Urine albumin and creatinine were measured
by chemiluminescence immunoassay (Siemens Immulite
2000, United States) and the Jaffe’ s kinetic method (Bio-
base-Crystal, Jinan, China) on the automatic analyzer, re-
spectively. ACR was calculated by dividing the urinary
albumin concentrations by the urinary creatinine con-
centrations and expressed in mg/g. Increased urinary al-
bumin excretion was defined according to the ACR
ranges greater or equal than 30 mg/g. The definition of
low-grade albuminuria was according to the highest
quartile of ACR in participants without increased urin-
ary albumin excretion (ACR greater or equal than
11 mg/g and less than 30 mg/g in the present study).
Chronic kidney disease (CKD) was defined as eGFR less
than 60 mL/min per 1.73 m2 or presence of albuminuria
(ACR greater or equal than 30 mg/g).
Statistical analyses
The statistical analyses were performed using SAS ver-
sion 9.2 (SAS Institute Inc., Cary, NC, USA). Totally, we
analyzed the effects of lipid parameters (TG, TC, HDL-
C, LDL-C, Non-HDL-C, Non-HDL-C/HDL-C and TG/
HDL-C) on clinical factors correlated with renal func-
tion (ACR, SCr and eGFR), prevalence of albuminuria
(low-grade albuminuria, increased urinary albumin ex-
cretion) and CKD.
Continuous variables are presented as the means ±
the standard deviations (SD) with the exception of
skewed variables, which were presented as medians
(interquartile ranges). Categorical variables are
expressed as numbers (proportions). FPG, TG, ACR,
HOMA-IR, Non-HDL-C/HDL-C, TG/HDL-C, SCr,
eGFR and MET-h/week were logarithmically transformed
prior to analysis due to non-normal distributions. Linear
regression analyses were used to test for trends across
groups. Differences between groups were tested with one-
way ANOVAs, and post hoc comparisons were performed
using the Bonferroni correction. Comparisons between
categorical variables were performed with the χ2 test.
Pearson’s correlation and multivariate linear regression
model were performed to evaluate the associations of
lipid parameters with ACR, SCr and eGFR. Unadjusted
and multivariate adjusted logistic regression analyses were
used to assess the prevalence of low-grade albuminuria,
increased urinary albumin excretion and CKD according
to elevated lipid profiles quartiles. Participants with CKD
were excluded from the analysis for risk of prevalent
low-grade albuminuria. The odds ratios (OR) and the
corresponding 95 % confidence intervals (95 % CI) were
calculated. Model 1 was unadjusted. Model 2 was ad-
justed for age and sex. Model 3 is further adjusted for
BMI, current smoking and drinking status, physical activ-
ity level, systolic blood pressure (SBP), and HbA1c.
Model 4 is further adjusted for previously diagnosed dia-
betes, cardiovascular diseases, hypertension and dyslipid-
emia. The relationships of lipid parameters with
increased urinary albumin excretion and CKD were also
explored within subgroups that stratified by age (≥55 or
< 55 years), degree of obesity (normal, overweight or
obesity), hypertension (yes or no), diabetes (yes or no)
and dyslipidemia (yes or no). In interaction analyses, we
examined separately for feasible associate factors that
could modify the relationship between albuminuria and
lipid measures. Tests for interaction were performed with
including simultaneously each strata factor, lipid parame-
ters quartiles and the respective interaction terms (strata
factor multiplied by lipid parameters quartiles) in the
final model.
All statistical tests were two-sided, and P values < 0.05
were considered statistically significant.
Results
Basic clinical characteristics of the study population
Among the 9730 enrolled subjects, the mean age was
55.9 ± 8.1 years and median ACR was 8.1 mg/g with
interquartile range 5.7 to 12.2 mg/g. There were 2274
(23.4 %) participants categorized as low-grade albumin-
uria, 639 (6.6 %) participants categorized as increased
urinary albumin excretion and 689 (7.1 %) participants cat-
egorized as CKD, respectively. The clinical and biochemical
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characteristics according to urinary albumin excretion sta-
tus were presented in Table 1. Compared subjects with nor-
mal urinary albumin excretion, those with low-grade
albuminuria or increased urinary albumin excretion had
significantly higher TG, Non-HDL-C, Non-HDL-C/HDL-C
and TG/HDL-C (all P < 0.05). Moreover, compared subjects
with low-grade albuminuria, those with increased urinary
albumin excretion presented with higher TG, Non-HDL-C/
HDL-C, TG/HDL-C and lower HDL-C level (all P < 0.05).
Associations between lipid parameters and clinical factors
correlated with renal function
As shown in Table 2, Pearson’s correlation analysis re-
vealed that TG, HDL-C, Non-HDL-C/HDL-C, TG/
HDL-C were significantly correlated with ACR, SCr and
eGFR (all P < 0.0001). By performing multivariate linear
regression analysis and further adjusted for age and
sex, we found that the associations were still persisted
(all P < 0.0001). However, TC and LDL-C were not
correlated with ACR in both Pearson’s correlation and
linear regression analysis.
Associations between lipid parameters and low-grade
albuminuria, increased urinary albumin excretion and
CKD
Figure 1 showed the prevalent low-grade albuminuria,
increased urinary albumin excretion and CKD in differ-
ent lipid parameters quartiles. The prevalence of albu-
minuria and CKD were tended to increase with the
elevated TG, Non-HDL-C, Non-HDL-C/HDL-C and
Table 1 Characteristics of study population by urinary albumin excretion status
Normal urinary albumin excretion Low-grade albuminuria Increased urinary albumin excretion P for trend
n ( % ) 6817 (70.1) 2274 (23.4) 639 (6.6)
ACR (mg/g) 6.7 (5.0–8.4) 14.7 (12.5–19.0)* 53.3 (37.8–94.6)*# <0.0001
Age (years) 55.5 ± 7.7 56.7 ± 8.4* 58.0 ± 9.6*# < 0.0001
Male [n (%)] 2097 (30.8) 501 (22.0) 188 (29.4) < 0.0001
BMI (kg/m2) 23.4 ± 3.2 24.0 ± 3.8* 24.7 ± 3.7*# < 0.0001
WC (cm) 81.1 ± 9.2 82.3 ± 9.9* 85.1 ± 10.4*# < 0.0001
SBP (mmHg) 124.2 ± 15.6 129.0 ± 16.9* 135.0 ± 18.9*# < 0.0001
DBP (mmHg) 74.6 ± 9.5 76.4 ± 10.4* 78.9 ± 11.0* < 0.0001
Current smoker [n (%)] 703 (10.6) 164 (7.4)* 74 (11.8) # 0.072
Current drinker [n (%)] 226 (3.4) 67 (3.1) 23 (3.7) 0.817
Physical activity (MET-h/week) 21.0 (10.5–45.0) 21.0 (10.5–42.0) 21.5 (10.5–42.0) 0.831
TG (mg/dL) 108.8 (79.6–157.5) 115.9 (82.3–169.9)* 137.2 (96.5–194.7)*# < 0.0001
TC (mg/dL) 199.6 ± 47.4 203.6 ± 48.7* 202.4 ± 52.0 0.002
HDL-C (mg/dL) 51.2 ± 13.9 51.1 ± 13.8 47.8 ± 12.8*# < 0.0001
LDL-C (mg/dL) 120.8 ± 36.5 122.2 ± 37.8 122.6 ± 39.0 0.067
Non-HDL-C (mg/dl) 148.4 ± 41.8 152.4 ± 43.2* 154.6 ± 46.3* < 0.0001
Non-HDL-C/HDL-C 2.9 (2.3–3.6) 3.0 (2.4–3.8)* 3.3 (2.6–4.0)*# < 0.0001
TG/HDL-C 2.2 (1.5–3.5) 2.3 (1.5–3.7)* 3.0 (1.9–4.5)*# < 0.0001
FPG (mmol/L) 5.4 (5.0–5.9) 5.5 (5.0–6.1)* 5.6 (5.1–6.7)*# < 0.0001
HbA1C (%) 6.0 ± 0.7 6.2 ± 1.0* 6.5 ± 1.5*# < 0.0001
HOMA-IR 1.67 (1.19–2.39) 1.88 (1.29–2.80)* 2.23 (1.45–3.48)*# < 0.0001
SCr (μmol/L) 67.0 (60.8–76.0) 65.0 (59.5–72.9)* 69.1 (60.9–81.1)*# 0.531
eGFR (ml/min per 1.73 m2) 110.9 (100.0–123.8) 111.5 (100.1–124.8) 106.4 (94.2–122.0)*# < 0.0001
Previous CVD (%) 205 (3.0) 78 (3.4) 35 (5.5)*# 0.003
Previous hypertension (%) 893 (13.1) 486 (21.4)* 198 (31.0)*# < 0.0001
Previous diabetes (%) 313 (4.6) 201 (8.8)* 90 (14.1)*# < 0.0001
Previous dyslipidemia (%) 325 (4.8) 124 (5.5) 49 (7.7)*# 0.002
1. Data were means ± SD or medians (interquartile ranges) for skewed variables or numbers (proportions) for categorical variables.
2. P for trend was calculated for the linear regression analysis tests across the groups. P values were for the ANOVA or χ2 analyses across the groups.
3. *P < 0.05 compared with normal urinary albumin excretion group; #P < 0.05 compared with low-grade albuminuria group.
4. ACR, urinary albumin to creatinine ratio; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG,
triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; HOMA-IR,
homeostasis model assessment of insulin resistance; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; CVD, cardiovascular diseases.
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TG/HDL-C quartiles (all P for trend < 0.001). For both
prevalent increased urinary albumin excretion and CKD,
no obvious trend differences were detected in subjects
with different quartiles of TC and LDL-C. The preva-
lence of low-grade albuminuria tended to increase with
lipid parameters quartiles except for HDL-C and LDL-C.
As shown in Table 3, in the univariable logistic regres-
sion analysis, participants were more likely to have low-
grade albuminuria with the elevated quartiles of TG, TC,
Non-HDL-C, Non-HDL-C/HDL-C and TG/HDL-C.
However, in the multivariable logistic regression, no sig-
nificant relationships between those lipid parameters
and low-grade albuminuria were observed. Similarly in
Table 3, in the univariable logistic regression analysis,
with the quartile change of HDL-C, Non HDL-C, Non-
HDL-C/HDL-C and TG/HDL-C, participants were more
likely to have prevalent increased urinary albumin excre-
tion and CKD. Further adjustments for other potential
confounding factors including age, sex, BMI, current
smoking and drinking status, physical activity level, SBP,
HbA1c, previously diagnosed diabetes, cardiovascular
diseases, hypertension and dyslipidemia, the associations
of those lipid measures with increased urinary albumin
excretion and CKD were still persisted.
Compare with other lipid parameters, TG/HDL-C
have shown the strongest correlation with increased
odds of both increased urinary albumin excretion and
CKD across all logistic regression models (Table 3). To
verify the stability of such results, we conducted strati-
fied analyses to determine the odds of increased urinary
albumin excretion and CKD with each quartile increase
of TG/HDL-C in different subgroups. As shown in
Figs. 2 and 3, such associations were not consistently the
same according to stratified factors. The associations of
TG/HDL-C with prevalent increased urinary albumin
excretion and CKD were significant in women strata,
both age strata (≥55 and < 55), BMI strata (normal and
overweight), both hypertension strata (yes and no),
both diabetes strata (yes and no) and subjects without
dyslipidemia strata. The difference in the subgroups
analysis was accompanied by a statistically significant
interaction term when stratified by sex (P = 0.021 for
increased urinary albumin excretion and P = 0.010 for
CKD).
Discussion
In this study of 9730 middle-aged and elderly Chinese,
we found significant discordant associations of lipid pa-
rameters with albuminuria and CKD. TG/HDL-C is a
better marker than other routine lipid measures for
identifying both increased urinary albumin excretion and
CKD, which should be given more consideration in the
clinical approach to risk reduction among those patients.
Our data do not support the association between rou-
tinely available lipid measures and prevalent low-grade
albuminuria.
Lipoprotein abnormalities have been identified as pos-
sible causes of renal function damage. Previous study
has shown that elevated TG levels and diminished HDL-
C levels, but not LDL-C, were associated with increased
risk of renal dysfunction and poor renal outcomes [27].
Significant associations between the TG/HDL-C and re-
duced eGFR or albuminuria have also been identified re-
cently in Korean and Japanese adults [28–30]. In
addition to the above lipid measures, a recent study also
found that Non-HDL-C/HDL-C is an independent risk
factor for the development of CKD [31]. Systemically
clarified correlations of different lipid measures with al-
buminuria and CKD would probably shed light on the
prevention and treatment of the diseases. Additionally,
growing evidence indicated that low-grade albuminuria
is associated with impaired kidney function and incident
cardiovascular diseases [32, 33]. Less is known concern-
ing the association between lipid profiles and low-grade
Table 2 Pearson’s correlation and multiple regression analysis of lipid parameters associated with ACR, SCr and eGFR
ACR (mg/g) SCr (μmol/L) eGFR (ml/min per 1.73 m2)
r P value Standardized β P value r P value Standardized β P value r P value Standardized β P value
TG (mg/dl) 0.09 < 0.0001 0.09 < 0.0001 0.23 < 0.0001 0.19 < 0.0001 −0.23 < 0.0001 −0.22 < 0.0001
TC (mg/dl) 0.01 0.177 −0.01 0.556 0.25 < 0.0001 0.29 < 0.0001 −0.37 < 0.0001 −0.33 < 0.0001
HDL-C (mg/dl) −0.05 < 0.0001 −0.07 < 0.0001 0.05 < 0.0001 0.19 < 0.0001 −0.21 < 0.0001 −0.23 < 0.0001
LDL-C (mg/dl) 0.002 0.846 −0.01 0.172 0.20 < 0.0001 0.22 < 0.0001 −0.29 < 0.0001 −0.26 < 0.0001
Non-HDL-C
(mg/dl)
0.03 0.002 0.02 0.123 0.27 < 0.0001 0.26 < 0.0001 −0.32 < 0.0001 −0.31 < 0.0001
Non-HDL-C/
HDL-C
0.06 < 0.0001 0.07 < 0.0001 0.20 < 0.0001 0.08 < 0.0001 −0.13 < 0.0001 −0.10 < 0.0001
TG/HDL-C 0.09 < 0.0001 0.10 < 0.0001 0.16 < 0.0001 0.06 < 0.0001 −0.09 < 0.0001 −0.06 < 0.0001
1. ACR, urinary albumin to creatinine ratio; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; SCr, serum creatinine; eGFR, estimated glomerular filtration rate.
2. ACR, SCr, eGFR, TG, Non-HDL-C/HDL-C and TG/HDL-C levels were logarithmically transformed to achieve a normal distribution.
3. r, correlation coefficient; β, regression coefficient; Multiple regression analysis is adjusted for age and sex.
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Fig. 1 Prevalence of low-grade albuminuria, increased urinary albumin excretion and CKD in quartiles of different lipid profiles
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albuminuria. In this study, compared with other lipid
measures, TG/HDL-C has shown the most significant
association with increased urinary albumin excretion
and CKD after adjustment for demographic and clinical
information. However, no association of lipid measures
with low-grade albuminuria was detected after adjust-
ment for same variables.
There are several reasons why the level of TG/HDL-C
may be superior to that of other lipid parameters in in-
creased urinary albumin excretion and CKD identifica-
tion. Elevated TG levels and decreased HDL-C levels
have been most strongly associated with increased risk
of renal dysfunction [27, 34]. Despite divergent under-
lying mechanisms, injury-induced cellular TG accumula-
tion can disrupt and damage cellular homeostasis.
According to the severity of the injury, TG accumulation
could result in renal tubular cell damage in vivo and
in vitro models [35]. As a medium of interaction with cell
surface proteins, HDL-C could promote TC clearance
from the circulation and decrease lipid deposition in the
arterial wall, which might slow the progression of
kidney dysfunction in patients with CKD [34, 36]. The
nature of TG to HDL-C ratio seems to be better corre-
lated with the development of CKD and albuminuria than
single measurement of either TG or HDL-C levels. More-
over, insulin resistance is associated with albuminuria and
the development of CKD in observational human studies
[37]. Compared with other metabolic markers, TG/
HDL-C in circulation is better correlated with insulin
resistance, which might therefore relevant with risk of
various adverse outcomes including renal dysfunction
[38]. Based on the results of the present study, the associ-
ation of TG/HDL-C with increased urinary albumin ex-
cretion and CKD was stronger in participants without
dyslipidemia. It is thus possible that TG/HDL-C could
represent the progression of renal insufficiency even in
the early stage of lipid metabolism abnormity.
Several limitations in this study require consideration.
First, we evaluated the urinary albumin excretion on a
spot morning urine sample. We admitted that multiple
Table 3 Association between lipid parameters and prevalent low-grade albuminuria, increased urinary albumin excretion and CKD
1-Quartile change of lipid parametersa
Model 1 Model 2 Model 3 Model 4
Low-grade albuminuria TG 1.10 (1.06–1.15) 1.10 (1.06–1.15) 1.01 (0.96–1.06) 1.01 (0.97–1.06)
TC 1.06 (1.02–1.11) 1.03 (0.98–1.07) 1.01 (0.96–1.05) 1.02 (0.97–1.06)
HDL-C 1.00 (0.96–1.05) 1.05 (1.01–1.10) 0.99 (0.95–1.04) 0.99 (0.94–1.04)
LDL-C 1.02 (0.98–1.07) 0.99 (0.95–1.04) 0.97 (0.93–1.02) 0.98 (0.94–1.03)
Non-HDL-C 1.07 (1.03–1.12) 1.05 (1.00–1.09) 1.00 (0.96–1.05) 1.01 (0.96–1.06)
Non-HDL-C/HDL-C 1.08 (1.04–1.13) 1.10 (1.05–1.15) 1.01 (0.96–1.06) 1.01 (0.96–1.07)
TG/HDL-C 1.08 (1.03–1.12) 1.09 (1.05–1.14) 0.99 (0.94–1.04) 0.99 (0.94–1.04)
Increased urinary albumin excretion TG 1.36 (1.27–1.47) 1.34 (1.24–1.44) 1.16 (1.07–1.26) 1.17 (1.08–1.27)
TC 1.03 (0.96–1.11) 1.01 (0.94–1.08) 0.95 (0.88–1.02) 0.96 (0.89–1.04)
HDL-C 1.25 (1.16–1.35) 1.26 (1.17–1.36) 1.17 (1.08–1.27) 1.16 (1.07–1.26)
LDL-C 1.04 (0.97–1.12) 1.02 (0.95–1.09) 0.96 (0.89–1.04) 0.98 (0.91–1.06)
Non-HDL-C 1.12 (1.04–1.20) 1.09 (1.01–1.17) 0.99 (0.91–1.07) 1.00 (0.93–1.08)
Non-HDL-C/HDL-C 1.28 (1.19–1.38) 1.25 (1.16–1.35) 1.09 (1.00–1.18) 1.10 (1.01–1.19)
TG/HDL-C 1.42 (1.32–1.53) 1.40 (1.30–1.51) 1.21 (1.11–1.31) 1.21 (1.11–1.31)
CKD TG 1.38 (1.29–1.48) 1.35 (1.25–1.45) 1.18 (1.09–1.28) 1.19 (1.10–1.28)
TC 1.05 (0.98–1.13) 1.03 (0.96–1.10) 0.97 (0.90–1.05) 0.99 (0.92–1.07)
HDL-C 1.25 (1.16–1.34) 1.25 (1.16–1.34) 1.16 (1.07–1.25) 1.15 (1.06–1.24)
LDL-C 1.05 (0.98–1.13) 1.03 (0.96–1.10) 0.98 (0.91–1.05) 0.99 (0.92–1.07)
Non-HDL-C 1.15 (1.07–1.23) 1.11 (1.04–1.20) 1.02 (0.94–1.10) 1.03 (0.96–1.11)
Non-HDL-C/HDL-C 1.32 (1.23–1.41) 1.28 (1.19–1.37) 1.11 (1.03–1.20) 1.12 (1.04–1.22)
TG/HDL-C 1.42 (1.32–1.53) 1.39 (1.30–1.50) 1.21 (1.11–1.31) 1.21 (1.11–1.31)
Data are odds ratios (95% confidence interval). Participants without low-grade albuminuria, increased urinary albumin excretion or CKD are defined as 0 and with
low-grade albuminuria, increased urinary albumin excretion or CKD as 1
Model 1 is unadjusted
Model 2 is adjusted for age and sex
Model 3 is further adjusted for BMI, current smoking and drinking status, physical activity level, SBP and HbA1c
Model 4 is further adjusted for previously diagnosed diabetes, cardiovascular diseases, hypertension and dyslipidemia
aAll variables were calculated for 1-Quartile increasing of lipid parameters except for HDL-C, which was calculated for 1-Quartile decreasing
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samples would provide more stable results for albumin
excretion [39]. However, results of spot urine samples
correlate well with those of 24 h or multiple urine sam-
ples [40, 41]. Use of spot samples for assessing urinary
ACR is therefore recommended as a reliable alternative to
perform in the out-patient clinic and large epidemiological
specimen collection. Second, although it is possible that
lipid measures is related with different degrees of albu-
minuria after controlled for extensive confounding factors,
other unmeasured confounders, such as cystatin-C,
should be also considered to evaluate to strength the find-
ings of the present study. Third, growing evidence has
suggested that abnormal lipid metabolism could contrib-
ute to the deterioration of renal function [27, 42]. How-
ever, due to the cross-sectional design of the present
study, we should be cautious regarding the interpretation
of whether dyslipidemia is a causal factor of or a conse-
quence of albuminuria and CKD. Fourth, medications
with angiotensin-converting enzyme inhibitors or angio-
tensin receptor blockers should have affected urinary
Fig. 3 Risk of prevalent CKD with each quartile increase of TG/HDL-C level in different subgroups
Fig. 2 Risk of prevalent increased urinary albumin excretion with each quartile increase of TG/HDL-C level in different subgroups
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albumin excretion and should be taken into account when
analyzing possible risk factors associated to proteinuria.
Absence of these data may influence risk estimates and re-
sult interpreting in this setting. Fifth, the results from the
present study of Chinese population might not be repre-
sentative of other races and younger people. The study
population was predominantly female, partially because
we invited residents with the mean age of 56 years and fe-
males are predominant in this age range in China.
Conclusion
In conclusion, the present study demonstrates discordant
associations of lipid parameters with renal insufficiency
and TG/HDL-C is a better marker for evaluating in-
creased urinary albumin excretion and CKD. No statisti-
cally significant association between lipid parameters and
prevalent low-grade albuminuria was found in our data.
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